ReviewNature reviews. Clinical oncology2011
Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Review in Nature reviews. Clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.World journal of surgical oncology · 2021Pooled it
- An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).Pharmacogenetics and genomics · 2019Trial
- Response of the replisome to araA and araC suggests a mechanism for arabinosyl nucleoside tolerance.The EMBO journal · 2026Article
- Insights into the activation patterns of 1,2-dithiolane unit in biofunctional molecules.Nature communications · 2026Article
- Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance ofESMO gastrointestinal oncology · 2025Article
- Integrative computational approaches identify haptoglobin inhibitors to modulate erythrocyte sedimentation rate in trauma-linked inflammatory and haematological malignancies.Frontiers in chemistry · 2025Article
- Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review.Oncology research · 2024Review
- Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients.Cancer chemotherapy and pharmacology · 2023Observational
- Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells.Journal of cancer research and clinical oncology · 2023Article
- Exosomes and their roles in the chemoresistance of pancreatic cancer.Cancer medicine · 2022Review
- Combination of Gemcitabine with Cell-Penetrating Peptides: A Pharmacokinetic Approach Using In Silico Tools.Biomolecules · 2019Article
- Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.British journal of clinical pharmacology · 2019Article
- Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.Journal of cellular and molecular medicine · 2019Article
- Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.British journal of cancer · 2018Article
- CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.Blood advances · 2018Observational
- Pancreatic Cancer Chemoresistance to Gemcitabine.Cancers · 2017Review
- Future paradigms for precision oncology.Oncotarget · 2016Review
- Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.Cancer chemotherapy and pharmacology · 2016Review
- Computational oncology--mathematical modelling of drug regimens for precision medicine.Nature reviews. Clinical oncology · 2016Review
- Metronomics: towards personalized chemotherapy?Nature reviews. Clinical oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing the efficacy of anticancer agents and avoiding toxic effects is a critical issue in clinical oncology. Identifying biomarkers that predict clinical outcome would ensure improved patient care. Gemcitabine is widely used to treat various solid tumors as a single agent or in combination with other drugs. The therapeutic index of gemcitabine is narrow, and abnormal pharmacokinetics leading to changes in plasma exposure is a major cause of adverse effects. A number of biomarkers have been proposed to predict efficacy of gemcitabine, focusing on molecular determinants of response identified at the tumor level. Genetic and functional deregulations that affect the disposition of a drug could be the reason for life-threatening adverse effects or treatment failure. In particular, deregulation of cytidine deaminase, the enzyme responsible for detoxification of most nucleotide analogs, should be examined. Identifying and validating biomarkers for pharmacogenetic testing before administration of gemcitabine is a step towards personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.